Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback